RenovoRx, Inc. Annual Report: A Plain-English Summary

I’ve put together this guide to help you understand how RenovoRx performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment strategy.

1. What does this company do?

RenovoRx is a medical technology company based in Mountain View, California. They created the RenovoCath, a device that delivers cancer drugs directly to tumors. Instead of flooding the whole body with chemotherapy, this device uses pressure to bathe the tumor in medication. This targeted approach allows for higher drug doses at the tumor site while reducing the harsh side effects of traditional intravenous chemotherapy.

2. Business performance: From "Idea" to "Sales"

This was a breakout year. RenovoRx moved from a research-focused company into a commercial business. In 2025, they generated $1.1 million in revenue from RenovoCath sales, a major jump from the near-zero revenue in 2024.

Their new sales team is gaining momentum. As of February 2026, 12 U.S. cancer centers use the device, and 21 more are currently evaluating it. That is 33 centers total—tripling their pipeline since early 2025. Because patients usually need 5 to 6 procedures, each new center creates a recurring revenue stream. With the current pricing, each active center represents roughly $50,000 to $75,000 in annual revenue.

3. The "Big Bet": The TIGeR-PaC Trial

The company’s main focus is their Phase III trial for "IAG" (Intra-Arterial Gemcitabine). This treatment combines their device with standard chemotherapy to treat pancreatic cancer.

Early data looks promising. An interim analysis showed a 6-month improvement in median survival rates compared to the current standard. Patients also experienced 65% fewer severe side effects. They expect to finish enrolling 200 patients by mid-2026 and hope for final results in 2027. They are using a "Bayesian" statistical design, which allows for earlier data checks. This helps them save cash by potentially stopping the trial early if the treatment proves effective.

4. Financial health and risks

RenovoRx is still losing money, reporting a loss of about $8.5 million for 2025. As of March 2026, they had 45 million shares outstanding and about $12 million in cash.

Because they aren't yet profitable, they rely on raising money from investors to operate. If they need more cash, they may issue more shares, which reduces your ownership percentage. Based on their current spending of $700,000 per month, their cash will last until mid-2027. Also, there is no guarantee the FDA will approve the final treatment. If the trial fails, the company loses its main growth driver, which would likely hurt the stock price.

5. Future outlook

The company aims for $400 million in annual U.S. sales for the RenovoCath, targeting 200 high-volume cancer centers. They also plan to expand into other cancers, like bile duct or liver cancer, which could create a multi-billion-dollar opportunity. They hold 9 U.S. patents, with protection extending through 2045, creating a strong barrier against competitors.

---

Final thought for your decision: RenovoRx is currently in a "prove it" phase. The investment case hinges on their ability to convert the 21 centers currently evaluating their device into long-term customers, and the successful completion of the TIGeR-PaC trial. If you are considering an investment, keep a close eye on their cash burn rate and any updates regarding the trial enrollment timeline.